Vaxcyte, Inc. (PCVX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Vaxcyte, Inc. (PCVX) closed at USD 65.27 on 2026-10-15, a change of +50 % over the past year, with a market capitalization of USD 10.01B.
Vaxcyte, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 65.27 |
| 2026-10-14 | 67.55 |
| 2026-10-13 | 66.80 |
| 2026-10-12 | 70.65 |
| 2026-10-09 | 71.38 |
| 2026-10-08 | 65.01 |
| 2026-10-07 | 66.96 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Vaxcyte, Inc. key figures
- Previous close
- USD 65.27 (2026-10-15)
- 1-year change
- +50 %
- Market cap
- USD 10.01B
- Enterprise value
- USD 8.1B
- P/E ratio (trailing)
- -8.35
- P/E ratio (forward)
- -9.00
- EPS (trailing)
- -7.62
- EPS (forward)
- -7.07
- PEG ratio
- n/a
- Price to book
- 3.34
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 12.15
- Employees
- 507
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Vaxcyte, Inc. and compare it with other stocks.
Analyze PCVXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Vaxcyte, Inc. shares.